Cutting Out The Middlemen? Trump’s Pricing Order Offers Opportunity On PBMs

Executive Order On Most-Favored-Nation Pricing Also Foresees Direct Sales

Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.

Could the executive order be an opportunity for the off-patent industry? (Shutterstock)

More from Drug Pricing

More from Business